Literature DB >> 34906968

Too Good to Be True? Evaluation of Colonoscopy Sensitivity Assumptions Used in Policy Models.

Carolyn M Rutter1, Pedro Nascimento de Lima1,2, Jeffrey K Lee3, Jonathan Ozik2,4.   

Abstract

BACKGROUND: Models can help guide colorectal cancer screening policy. Although models are carefully calibrated and validated, there is less scrutiny of assumptions about test performance.
METHODS: We examined the validity of the CRC-SPIN model and colonoscopy sensitivity assumptions. Standard sensitivity assumptions, consistent with published decision analyses, assume sensitivity equal to 0.75 for diminutive adenomas (<6 mm), 0.85 for small adenomas (6-10 mm), 0.95 for large adenomas (≥10 mm), and 0.95 for preclinical cancer. We also selected adenoma sensitivity that resulted in more accurate predictions. Targets were drawn from the Wheat Bran Fiber study. We examined how well the model predicted outcomes measured over a three-year follow-up period, including the number of adenomas detected, the size of the largest adenoma detected, and incident colorectal cancer.
RESULTS: Using standard sensitivity assumptions, the model predicted adenoma prevalence that was too low (42.5% versus 48.9% observed, with 95% confidence interval 45.3%-50.7%) and detection of too few large adenomas (5.1% versus 14.% observed, with 95% confidence interval 11.8%-17.4%). Predictions were close to targets when we set sensitivities to 0.20 for diminutive adenomas, 0.60 for small adenomas, 0.80 for 10- to 20-mm adenomas, and 0.98 for adenomas 20 mm and larger.
CONCLUSIONS: Colonoscopy may be less accurate than currently assumed, especially for diminutive adenomas. Alternatively, the CRC-SPIN model may not accurately simulate onset and progression of adenomas in higher-risk populations. IMPACT: Misspecification of either colonoscopy sensitivity or disease progression in high-risk populations may affect the predicted effectiveness of colorectal cancer screening. When possible, decision analyses used to inform policy should address these uncertainties.See related commentary by Etzioni and Lange, p. 702. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2022        PMID: 34906968      PMCID: PMC8983491          DOI: 10.1158/1055-9965.EPI-21-1001

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.090


  46 in total

1.  A unified approach to the Richards-model family for use in growth analyses: why we need only two model forms.

Authors:  Even Tjørve; Kathleen M C Tjørve
Journal:  J Theor Biol       Date:  2010-09-08       Impact factor: 2.691

2.  Colorectal cancer screening: recommendations of the U.S. Preventive Services Task Force. American Gastroenterological Association.

Authors:  B Levin; J H Bond
Journal:  Gastroenterology       Date:  1996-11       Impact factor: 22.682

3.  Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial.

Authors:  Wendy S Atkin; Rob Edwards; Ines Kralj-Hans; Kate Wooldrage; Andrew R Hart; John M A Northover; D Max Parkin; Jane Wardle; Stephen W Duffy; Jack Cuzick
Journal:  Lancet       Date:  2010-04-27       Impact factor: 79.321

4.  Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies: Modeling Study for the US Preventive Services Task Force.

Authors:  Amy B Knudsen; Ann G Zauber; Carolyn M Rutter; Steffie K Naber; V Paul Doria-Rose; Chester Pabiniak; Colden Johanson; Sara E Fischer; Iris Lansdorp-Vogelaar; Karen M Kuntz
Journal:  JAMA       Date:  2016-06-21       Impact factor: 56.272

5.  Annual report to the nation on the status of cancer, 1975-2003, featuring cancer among U.S. Hispanic/Latino populations.

Authors:  Holly L Howe; Xiaocheng Wu; Lynn A G Ries; Vilma Cokkinides; Faruque Ahmed; Ahmedin Jemal; Barry Miller; Melanie Williams; Elizabeth Ward; Phyllis A Wingo; Amelie Ramirez; Brenda K Edwards
Journal:  Cancer       Date:  2006-10-15       Impact factor: 6.860

6.  The evolution of cancer of the colon and rectum.

Authors:  T Muto; H J Bussey; B C Morson
Journal:  Cancer       Date:  1975-12       Impact factor: 6.860

7.  Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies.

Authors:  D K Rex; C S Cutler; G T Lemmel; E Y Rahmani; D W Clark; D J Helper; G A Lehman; D G Mark
Journal:  Gastroenterology       Date:  1997-01       Impact factor: 22.682

8.  Aspirin and folic acid for the prevention of recurrent colorectal adenomas.

Authors:  Richard F A Logan; Matthew J Grainge; Vic C Shepherd; Nicholas C Armitage; Kenneth R Muir
Journal:  Gastroenterology       Date:  2007-10-10       Impact factor: 22.682

9.  Clinical significance of small colorectal polyps.

Authors:  James M Church
Journal:  Dis Colon Rectum       Date:  2004-03-04       Impact factor: 4.585

10.  Adenoma detection rate and risk of colorectal cancer and death.

Authors:  Douglas A Corley; Christopher D Jensen; Amy R Marks; Wei K Zhao; Jeffrey K Lee; Chyke A Doubeni; Ann G Zauber; Jolanda de Boer; Bruce H Fireman; Joanne E Schottinger; Virginia P Quinn; Nirupa R Ghai; Theodore R Levin; Charles P Quesenberry
Journal:  N Engl J Med       Date:  2014-04-03       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.